As it re-thinks its business model, Big Pharma has revamped its playbook on many fronts, entering previously unappealing niche markets that draw it closer to customers.
But few pharma companies have ventured far into critical care, a highly specialized area that seems, on the surface, to fit well with the new world thinking. The best approaches...